Amelioration of lead toxicity on rat liver with Vitamin C and silymarin supplements.
The aim of the present study was to investigate the impact of the combined administration of Vitamin C and silymarin on lead toxicity. Male albino rats were subdivided into three groups: the first was a control group, the second received lead acetate in diet as 500 mg/kg diet daily, the third received the same lead acetate dose and supplemented with Vitamin C (1 mg/100g body weight) and silymarin (1 mg/100g body weight) by gastric tube three times per week. Blood samples were taken after 2, 4 and 6 weeks of treatment. Significant lead-induced elevations in serum ALT, AST, GGT and ALP activities were observed after different periods of treatment. However, serum LDLc was decreased. The intensities of RNA and apoptotic fragments of DNA were measured as optical density by Gel-pro program. Lead acetate decreased the intensity of DNA at 6 weeks and induced apoptotic DNA fragments reversibly with time. After 2 weeks of lead administration dilation and congestion of terminal hepatic veins and portal vein branches were observed. Lead also induced hepatocyte proliferation without any localized distribution among zones 1-3. Portal inflammatory infiltrate with disruption of the limiting plates (interface hepatitis), steatosis, apoptosis and mild fibrosis were detected especially by sixth week of lead administration. Combined treatment of lead-exposed animals with Vitamin C and silymarin showed marked improvement of the biochemical, molecular and histopathological findings. These experimental results strongly indicate the protective effect of Vitamin C and silymarin against toxic effects of lead on liver tissue.
Shalan
M G
MG
Biological and Geological Sciences Department, Al-Arish Faculty of Education, Suez Canal University, Center of Town, Al-Arish, North Sinai 02, Egypt. mohamedshalan@yahoo.com
Mostafa
M S
MS
Hassouna
M M
MM
El-Nabi
S E Hassab
SE
El-Refaie
A
A
D000284:Administration, Oral; D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D008078:Cholesterol, LDL / Q000378:metabolism; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D022781:Hepatocytes / Q000187:drug effects / Q000473:pathology; D007855:Lead Poisoning / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D008099:Liver / Q000187:drug effects* / Q000473:pathology; D008297:Male; D009942:Organometallic Compounds / Q000633:toxicity*; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D012838:Silymarin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000637:Transaminases / Q000378:metabolism
D008078:Cholesterol, LDL; D009942:Organometallic Compounds; D020011:Protective Agents; D012838:Silymarin; D000637:Transaminases; D000469:Alkaline Phosphatase; D001205:Ascorbic Acid; C008261:lead acetate